VANCOUVER, Canada — September 17, 2026
Clearmind Medicine announced that its Chief of Global Impact, Mary-Elizabeth Gifford, testified at an FDA-convened federal hearing on the potential future therapeutic use of psychedelic drugs in Washington, D.C. on September 14, 2026. Invited to address patient access, Gifford shared insights from Clearmind’s clinical research at Yale University and Johns Hopkins University and discussed the potential role of non-hallucinogenic psychedelic-derived neuroplastogens in developing scalable treatment models. The hearing brought together FDA officials and federal health agencies to gather perspectives on patient access, provider training, patient safety and data standardization.
FDA Hearing Examines Future Therapeutic Use of Psychedelics
The FDA hearing provided a dedicated federal forum for discussion of potential therapeutic applications of psychedelic drugs, with participation from senior representatives of the FDA, Substance Abuse and Mental Health Services Administration, National Institutes of Health and Veterans Health Administration. Clearmind said approximately 1,800 participants attended in person and virtually. Gifford told the federal panel that next-generation neuroplastogenic compounds designed to retain neuroplasticity-enhancing effects without hallucinogenic activity could potentially reduce the need for intensive supervised dosing. Clearmind believes such an approach could support broader patient access by potentially integrating treatment into existing medical-care infrastructure.
MEAI Advances in Alcohol Use Disorder Development
Clearmind’s lead candidate MEAI is being evaluated in FDA-approved clinical research for alcohol use disorder (AUD) at Yale University Medical School and Johns Hopkins University. The company describes MEAI as a non-hallucinogenic, psychedelic-derived neuroplastogen and says the candidate has advanced into a Phase 2a clinical trial. Clearmind is developing MEAI as a potential treatment for AUD, while investigating the broader therapeutic potential of its neuroplastogen platform across neuropsychiatric, metabolic and addiction disorders. The company’s development strategy is focused on generating clinical evidence for compounds intended to provide therapeutic effects without the hallucinogenic properties associated with traditional psychedelics.
Advertisement
Clearmind Expands Federal Engagement Around Neuroplastogens
Clearmind’s participation in the FDA hearing adds a policy and patient-access dimension to its clinical development strategy, as the company continues advancing non-hallucinogenic psychedelic-derived therapies. CEO Adi Zuloff-Shani said the company views MEAI as part of its effort to develop treatments that could ultimately combine clinical effectiveness with broader accessibility. Clearmind currently reports 19 patent families and 32 granted patents covering its intellectual property portfolio. As federal agencies examine potential frameworks for psychedelic medicines, Clearmind is positioning its neuroplastogen platform around the development of regulated therapeutic products for underserved conditions, with AUD serving as the lead clinical focus.
SourceClearmind Medicine, press release
